This association was first tested in the HBCx-22 TamR PDX, established from a ER+ breast cancer with a PIK3R1 mutation and PTEN protein loss, and rendered resistant to tamoxifen in vivo [12, 13]. This evidence concerns the gene PTEN and breast carcinoma.